2026 MCM | New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer

2026 MCM | New and Evolving Directions in the Treatment of HER2 Positive Breast Cancer

Overview

NA

Target Audience

Physicians
Nurses
Pharmacists
Physician Associates

This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.

Faculty

Mark Pegram, MD

Date of Release

January 24th, 2026